期刊文献+

血小板衍化内皮细胞生长因子在胰腺癌组织中的表达及其临床意义 被引量:1

Clinical significance of PD-ECGF expression in human pancreatic carcinoma
下载PDF
导出
摘要 目的:观察血小板衍化内皮细胞生长因子(PD-ECGF)在胰腺癌组织中的表达,探讨其临床意义.方法:利用Elivison免疫组织化学法检测36例手术切除的胰腺癌及21例癌旁正常胰腺组织,以及胃癌、食管癌、肝癌、结肠癌、肺癌及乳腺癌组织各10例中PD-ECGF的表达.分析PD-ECGF与胰腺癌大小、分化程度及淋巴结转移的相关性.结果:PD-ECGF在胰腺癌组织中的表达阳性率显著高于在癌旁正常胰腺组织(88.9%vs28.6%,P<0.01).PD-ECGF在结肠癌、肝癌、乳腺癌、食管癌、胃癌及肺癌组织中的表达阳性率为60%、70%、80%、90%、90%及80%.Ⅱ-Ⅳ期胰腺癌组织中PD-ECGF的表达阳性率显著高于Ⅰ期胰腺癌组织(100%vs75%,P<0.05).结论:PD-ECGF为一种非特异性的肿瘤相关因子,其可能与胰腺癌的病程进展有关. AIM:To investigate the expression of plateletderived endothelial cell growth factor (PDECGF) in human pancreatic carcinoma and evaluate its clinical significance.METHODS:Immunohistochemistry was used to detect the expression of PD-ECGF in 36 paraffinembedded pancreatic carcinoma specimens,21 tumor-adjacent normal tissue specimens,and 60 cancerous specimens derived from other tissues (stomach,colon,esophagus,liver,lung and breast;10 specimens each).The expression of PD-ECGF in different tissues was compared.The correlation between PD-ECGF expression and clinical parameters in pancreatic carcinoma was analyzed.RESULTS:The positive rate of PD-ECGF in pancreatic carcinoma was higher than that in tumor-adjacent normal tissue (88.9% vs 28.6%,P 〈0.01).The positive rates of PD-ECGF in cancerous colon,liver,breast,esophagus,stomach and lung tissues were 60%,70%,80%,90%,90% and 80%,respectively.The positive rate of PD-ECGF in pancreatic carcinoma at stage Ⅱ-Ⅳ was higher than that at stage Ⅰ (100% vs 75%,P〈 0.05).CONCLUSION:PD-ECGF is an organ-unspecific tumor-associated protein that may be associated with the progression of pancreatic carcinoma.
出处 《世界华人消化杂志》 CAS 北大核心 2010年第2期143-148,共6页 World Chinese Journal of Digestology
基金 江苏省"六大人才高峰"基金资助项目 No.2006073 南通市社会发展基金资助项目 No.S2007028~~
关键词 血小板衍化内皮细胞生长因子 胰腺癌 胰腺癌标志物 PD-ECGF Pancreatic carcinoma Marker for pancreatic carcinoma
  • 相关文献

参考文献6

二级参考文献19

  • 1赵彤,朱梅刚,黄宗义,张亚历,张素娟,李梅芳.肺癌癌基因蛋白产物同步检测的对比分析[J].癌症,1995,14(1):13-15. 被引量:54
  • 2谷化平,冯和平,徐志勇,苏红.免疫组化在恶性黑色素瘤诊断中的作用[J].中国肿瘤临床,1996,23(8):599-600. 被引量:4
  • 3Isaka S,Sawai K, Tomiic M, et al. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in cervical intraepithelial neoplasia. Int J Oncol, 2002,21 : 281-287.
  • 4Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early state breast carcinoma. J Natl Cancer Inst, 1992,84:1875.
  • 5Fromowitz FB, Viola MV, Chao S, et al. Ras p21 Expression in the progression,sion of breast cancer. Hum Pathol, 1987,18:1268-1275.
  • 6Hanahan D, Folkrnan J. Patterns and emerging mechanism of the angiogenie switch during tumorgenesis. Cell, 1996,86:353.
  • 7Matsushita S, Nitanda T,Furukawa T, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumer. Cancer Res, 1999,59:1911-1916.
  • 8Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst,1996,88:1110-1117.
  • 9Koukourakis MI, Giatromanolaki A, Kakolyris S, et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in nonsmallcell lung cancer: Impact on tumour neoangiogenesis and survival. Br J Cancer, 1998,77:1696-1703.
  • 10Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res, 1999,59 : 1911-1916.

共引文献1404

同被引文献67

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部